Plasma Protein Growth Arrest–Specific 6 Levels Are Associated With Altered Glucose Tolerance, Inflammation, and Endothelial Dysfunction by Hung, Yi-Jen et al.
Plasma Protein Growth Arrest–Speciﬁc 6
Levels Are Associated With Altered
Glucose Tolerance, Inﬂammation, and
Endothelial Dysfunction
YI-JEN HUNG, MD
1
CHIEN-HSING LEE, MD
1,2 NAIN-FENG CHU, MD, PHD
3,4
YI-SHING SHIEH, MD, PHD
5,6
OBJECTIVE — Plasmaproteingrowtharrest–speciﬁc6(Gas6)isimportanttotheinﬂamma-
toryprocessandisinvolvedinthedevelopmentofdiabeticrenalandvascularcomplications.We
set out to determine whether plasma Gas6 levels are associated with altered glucose tolerance,
insulin sensitivity, inﬂammation, and endothelial dysfunction.
RESEARCH DESIGN AND METHODS — A total of 278 adults, including 96 with
normal glucose tolerance (NGT), 82 with impaired glucose tolerance (IGT), and 100 with type
2 diabetes were recruited. Plasma Gas6 concentration and biochemical, proinﬂammatory, and
endothelial variables were determined. Insulin sensitivity was examined by homeostasis model
assessment.
RESULTS — Plasma Gas6 concentration was signiﬁcantly lower among patients with type 2
diabetes compared with subjects with NGT (P  0.001). The plasma Gas6 value was inversely
correlated with fasting glucose, tumor necrosis factor (TNF)-, interleukin (IL)-6, and vascular
cell adhesion molecule (VCAM)-1. In multivariate logistic regression analysis, after adjustment
for established diabetes risk factors, higher plasma Gas6 concentrations were signiﬁcantly asso-
ciatedwithadecreasedriskoftype2diabetes.Moreover,theassociationbecameslightlystronger
after further adjustment for TNF-, IL-6, high-sensitive C-reactive protein, E-selectin, intercel-
lular adhesion molecule-1, and VCAM-1.
CONCLUSIONS — Plasma Gas6 is associated with altered glucose tolerance, inﬂammation,
and endothelial dysfunction. It also may represent a novel independent risk factor of type 2
diabetes and a potential surrogate marker of inﬂammation and endothelial dysfunction.
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T
he epidemic of type 2 diabetes and
impaired glucose tolerance (IGT) is
one of the main causes of morbidity
and mortality worldwide (1). In both dis-
orders, tissues such as muscle, fat, liver,
and endothelial cells become less respon-
sive or, in some cases, resistant to insulin
(2). Although it is well established that
insulin resistance and impaired insulin
secretion are central to the pathogenesis
oftype2diabetes,ithasbeenunclearhow
these abnormalities arise and how they
are related to many different clinical and
biochemical features common in type 2
diabetes, including central obesity, hy-
pertension, accelerated atherosclerosis,
chronic inﬂammation, dyslipidemia, and
disordered hemostasis.
Protein growth arrest–speciﬁc 6
(Gas6) was the last addition to the family
ofplasmavitaminK–dependentproteins.
Gas6 was cloned and characterized in
1993 and found to be similar to plasma
anticoagulant protein S (3). Soon after, it
was recognized as a growth factor–like
molecule, as it interacted with receptor
tyrosine kinases of the TAM (Tyro-3, Axl,
Mer) family (4). The Gas6/TAM system
regulates an intriguing mix of processes,
including cell survival and proliferation,
cell adhesion and migration, blood clot
stabilization, and inﬂammatory cytokine
release (5–8). Therefore, the role of the
Gas6/TAM system has been found to be
important in inﬂammation; hemostasis;
autoimmune disease; nervous, reproduc-
tive,andvascularsystems;andcancer(9).
Recently, several reports (10–12) re-
vealed that the Gas6/TAM system was in-
volved in the pathogenesis of diabetic
renal and vascular disease. Expression of
Gas6/TAM was increased in the glomeru-
lusofdiabeticrats,whichledtomesangial
and glomerular hypertrophy (10). In vas-
cular smooth muscle cells (VSMCs),
Gas6/TAM signaling increased cell sur-
vival in the presence of low glucose and
increasedcellmigrationinthepresenceof
high glucose (11). VSMC migration was
increased in patients with diabetes, and
diabetes accelerated the accumulation of
VSMCs in atherosclerotic lesions (12).
These preclinical studies indicate that
Gas6/TAM likely represents an important
pathogenic mechanism for renal and car-
diovascular complications associated
with diabetes. However, little is known
abouttheclinicalsigniﬁcanceoftheGas6/
TAMsysteminpatientswithdiabetesand
its association with various biochemical
variables that are common in diabetic pa-
tients. We have addressed this issue by
conducting a cross-sectional study to de-
termine whether plasma Gas6 levels are
associated with altered glucose tolerance,
insulin sensitivity, inﬂammatory, and en-
dothelialdysfunctionmarkersinhumans.
RESEARCH DESIGN AND
METHODS— A total of 278 adults
were recruited from the outpatient clinics
of Tri-Service General Hospital, Taipei,
Taiwan. Criteria for inclusion into this
studywereasfollows:20–75yearsofage;
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2; absence of infection
within the previous weeks; absence of
taking oral anticoagulants and antidiabe-
tes therapy, including oral hypoglycemic
agents,insulin,andglucagon-likepeptide
1; and absence of malignant tumor his-
tory. Exclusion criteria included women
who were pregnant or breast feeding; pa-
tients with impaired renal function (se-
rum creatinine 132.6 mol/l); patients
with abnormal serum aspartate amino-
transferase or alanine aminotransferase
(2.5 times above the upper normal
ranges); patients with acute or chronic
pancreatitis; patients with a history of ce-
rebrovascular accident, myocardial in-
farction, or heart failure; patients with
autoimmune disorders or psychiatric dis-
eases, including mood disorders and
alcoholism; and patients taking concom-
itant drugs such as -blockers, diuretics,
cholestyramine, or systemic steroids. A
75-g oral glucose tolerance test (OGTT)
was performed in all subjects after they
had fasted for at least 10 h. According to
the American Diabetes Association crite-
ria,participantsweredividedintonormal
glucose tolerance (NGT; n  96, fasting
glucose 5.6 mmol/l with a 2-h postload
plasma glucose of 7.8 mmol/l), IGT
(n82,fastingglucose7.0mmol/land
2-h postload glucose between 7.8 and
11.1 mmol/l), and previously unknown
type 2 diabetes (n  100, fasting glucose
7.0 mmol/l or 2-h postload glucose
11.1 mmol/l). The institutional review
board of the Tri-Service General Hospital
approved the protocol, and all subjects
gave written informed consent.
Analytic methods
After 10 h of fasting, blood samples were
obtainedtodetermineplasmaglucose,in-
sulin, creatinine, and lipid proﬁles.
Plasma circulating high-sensitive C-reac-
tive protein (hsCRP), tumor necrosis fac-
tor(TNF)-,andinterleukin(IL)-6levels;
E-selectin; intercellular adhesion mole-
cule(ICAM)-1;andvascularcelladhesion
molecule (VCAM)-1 were subsequently
measured. Serum total cholesterol, tri-
glycerides, and LDL cholesterol were
measured using the dry, multilayer ana-
lytical slide method in the Fuji Dri-Chem
3000 analyzer (Fuji Photo Film, Tokyo,
Japan). The intra-assay and interassay co-
efﬁcients of variation (CVs) for LDC cho-
lesterol were 0.8 and 2.5%, respectively.
Serum levels of HDL cholesterol were de-
termined by an enzymatic cholesterol as-
say method after dextran sulfate
precipitation.Theintra-assayandinteras-
say CVs for HDL cholesterol were 1.1 and
1.7%, respectively. The levels of A1C
wereevaluatedbytheion-exchangehigh-
pressure liquid chromatography method
(Variant II; Bio-Rad, Los Angeles, CA).
The intra-assay and interassay CVs for
A1C were 1.3 and 2.2%, respectively.
Plasma glucose concentrations were de-
termined by the glucose oxidase method
on a Beckman Glucose Analyzer II (Beck-
man Instruments, Fullerton, CA). The in-
tra-assay and interassay CVs for glucose
were 0.6 and 1.5%, respectively. Plasma
insulin was measured with a commercial
immunoradiometric kit (BioSource Eu-
rope, Nivelles, Belgium). The intra-assay
and interassay CVs for insulin were 2.2
and 6.5%, respectively. Plasma hsCRP
levels were measured using the Tina-
quant (Latex) high-sensitivity assay
(Roche,Mannheim,Germany).Theintra-
assay and interassay CVs for hsCRP were
3.7 and 4.9%, respectively. Serum IL-6
concentrations were determined by a hu-
man high-sensitivity enzyme-linked im-
munosorbent assay (ELISA) (Besancon,
France). The intra-assay and interassay
CVs for IL-6 were 1.5 and 5.3%, respec-
tively. Serum TNF- was measured with
the Biotrak high-sensitivity human ELISA
kit from Amersham Biosciences (Buck-
inghamshire, U.K.). The intra-assay and
interassay CVs for TNF- were 3.5 and
5.3%, respectively. Levels of E-selectin,
ICAM-1, and VCAM-1 were measured by
commercial ELISA (R&D Systems, Min-
neapolis, MN). The intra-assay and inter-
assay CVs for E-selectin were 4.5 and
6.2%, respectively; for ICAM-1 were 3.5
and 7.1%, respectively; and for VCAM-1
were 5.0 and 8.7%, respectively. All con-
centrationsoftheabovebiochemicalvari-
ables were determined in duplicate, and
the values of the two samples were aver-
aged. Insulin sensitivity was assessed us-
ing the homeostasis model assessment
(HOMA), in which the HOMA of insulin
resistance (HOMA-IR)  ([fasting insulin
{U/ml}]  [fasting glucose {mmol/l}])/
22.5 (13).
Measurement of Gas6
The Gas6 protein was measured with a
sandwich ELISA. The method has been
validatedaccordingtotheFoodandDrug
Administration guidelines in a previous
study (intra-assay and interassay CVs
were6.5and8.5%,respectively,meanre-
covery on 10 patients of 97%, lower limit
of quantiﬁcation 0.26 ng/ml) (14).
Brieﬂy, a 96-well microtitre plate was
coated overnight at room temperature
with 4 g/ml of polyclonal mouse anti-
human Gas6 antibody (R&D Systems,
Lille, France). After three washes with
0.05% Tween 20 in PBS, wells were
blocked with 1% BSA in PBS for 1 h at
room temperature. Three additional
washes were then performed and 100 l
plasma or standards (recombinant hu-
man Gas6; R&D Systems) were added for
2 h at room temperature. Washes were
repeated and 100 ng/ml biotinylated
monoclonal goat anti-human Gas6 anti-
body(R&DSystems)wasaddedfor2hat
room temperature. Detection was per-
formed with peroxydase-conjugated
streptavidin. Measurements were re-
peated three times.
Statistical methods
Descriptive results of continuous vari-
ables were expressed as means  SE.
Before statistical analysis, normal distri-
bution and homogeneity of the variables
wereevaluatedusingLevenetestforqual-
ity of variance, and variables were then
given a base logarithmic transformation if
necessary. The parameters HOMA-IR,
fasting insulin, triglycerides, TNF-,
IL-6,hsCRP,andGas6wereanalyzedand
tested for signiﬁcance on a log scale. We
used unpaired t test and ANOVA test
(with post hoc least signiﬁcant difference
test) for comparisons of quantitative vari-
ables. Bonferroni adjustment for multiple
comparisons among subgroups was ana-
lyzed,andthecorrectedPvalueof0.0025
was considered as statistical signiﬁcance.
Relationships between variables were
tested using Spearman rank-order corre-
lations and partial correlation analysis af-
ter adjusting for age. Multivariate logistic
regression analysis, with type 2 diabetes
as dependent variable, was used to study
the independent determinants of plasma
Gas6 and other covariates. The statistical
analyseswereperformedusingSPSS(ver-
sion 13.0; SPSS, Chicago, IL).
RESULTS— Characteristics of the
subjects according to glucose tolerance
status are shown in Table 1. Patients with
type 2 diabetes had higher BMI, waist-to-
hip ratio, blood pressure, HOMA-IR, tri-
glycerides, hsCRP, E-selectin, and
ICAM-1 and lower HDL cholesterol than
subjects with NGT. Plasma Gas6 concen-
trations were signiﬁcantly lower among
patientswithtype2diabetes(11.50.42
ng/ml)comparedwithsubjectswithNGT
(14.30.66ng/ml)(P0.001),asillus-
trated in Fig. 1. In all subjects as a whole,
the plasma Gas6 value was signiﬁcantly
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IL-6, and VCAM-1 after adjustment for
age (Table 2).
A multivariate logistic regression
analysis to investigate whether plasma
Gas6 values were related to type 2 diabe-
tes independent from other established
diabetes risk factors is shown in Table 3.
After adjustment for age, sex, BMI, waist-
to-hip ratio, blood pressure, smoking,
and alcohol consumption, higher plasma
Gas6 concentrations were signiﬁcantly
associated with a decreased risk of type 2
diabetes (type 2 diabetes versus NGT,
0.93 [0.87–0.99]; type 2 diabetes versus
IGT	NGT, 0.94 [0.89–0.99]). This as-
sociation remained signiﬁcant after fur-
ther adjustment for other covariates
(including TNF-, IL-6, and hsCRP).
Moreover,theassociationbecameslightly
stronger after further adjustment for
TNF-, IL-6, hsCRP, E-selectin, ICAM-1,
and VCAM-1 (type 2 diabetes versus
NGT, 0.90 [0.83–0.97]; type 2 diabetes
versus IGT	NGT, 0.92 [0.86–0.98]).
CONCLUSIONS — Numerous stud-
ieshaveshownthattheGas6/TAMsystem
regulates cell survival, proliferation, mi-
gration, adhesion, and phagocytosis.
Consequently, altered activity/expression
of Gas6/TAM components has been de-
tected in a variety of pathologies such as
inﬂammation, coagulopathy, cancer, au-
toimmune disease, and diabetic vascular
and renal diseases (9). However, direct
clinical evidence of the Gas6/TAM system
is lacking. Our results, described for the
ﬁrst time herein, revealed that plasma
Figure 1—Plasma Gas6 concentrations in subjects with NGT, subjects with IGT, and patients
withtype2diabetes.Thelinesrepresentthemedianvaluesineachgroup.Thetype2diabeticgroup
had signiﬁcantly lower plasma Gas6 levels than those with NGT (P  0.001).
Table 1—Anthropometric and biochemical variables among different glucose tolerance
subjects
NGT IGT Type 2 diabetes P value*
n 96 82 100
Age (years) 50.2  1.54 56.2  1.45 52.4  1.53 0.026
Sex (male/female) 43/53 26/56 57/43 0.003
BMI (kg/m
2) 23.9  0.37 25.4  0.50 26.0  0.39 0.002†
Waist-to-hip ratio 0.85  0.01 0.86  0.01 0.90  0.01 <0.001†
Blood pressure (mmHg)
Systolic 118.8  1.67 125.0  1.77 126.2  1.80 0.006†
Diastolic 76.9  0.91 78.1  1.16 81.1  0.91 0.008†
OGTT glucose (mmol/l)
Fasting glucose 5.05  0.06 5.42  0.07 8.30  0.44 <0.001†
2-h glucose 6.32  0.09 9.29  0.10 16.9  0.54 <0.001†
OGTT insulin (pmol/l)
Fasting insulin‡ 54.0  3.85 75.5  11.82 84.1  6.19 0.013†
2-h insulin‡ 388.2  32.5 659.1  61.49 528.2  52.05 0.001
A1C (%) 5.6  0.03 6.0  0.05 8.2  0.33 <0.001†
HOMA-IR‡ 2.04  0.15 3.19  0.61 4.85  0.38 <0.001†
Triglycerides (mmol/l)‡ 2.94  0.17 3.64  0.27 4.97  0.30 <0.001†
HDL cholesterol (mmol/l) 1.49  0.05 1.45  0.06 1.18  0.03 <0.001†
Inﬂammatory markers
TNF- (ng/ml)‡ 3.19  0.20 3.20  0.21 3.31  0.23 0.914
IL-6 (pg/ml)‡ 2.6  0.45 4.5  1.31 5.9  1.44 0.113
hsCRP (mg/l)‡ 0.70  0.08 0.92  0.09 1.15  0.10 0.002†
Endothelial dysfunction markers
E-selectin (ng/ml) 45.1  1.92 47.4  2.54 60.9  3.00 <0.001†
VCAM-1 (ng/ml) 527.6  31.08 506.7  38.72 660.2  40.38 0.006†
ICAM-1 (ng/ml) 248.8  9.08 244.9  8.36 293.6  10.39 <0.001†
Gas6 (ng/ml)‡ 14.3  0.66 13.3  0.63 11.5  0.42 0.002†
Data are means  SE. *Assessed by one-way ANOVA, data shown as mean  standard error mean. †P 
0.0025, NGT vs. type 2 diabetes. All assessed by post hoc least signiﬁcant difference test. ‡The logarithms of
these variables were used for the analysis. Boldface indicates statistical signiﬁcance.
Table 2—Age-adjusted Spearman partial
correlationcoefﬁcientsbetweenplasmaGas6
concentration and biochemical variables
Spearman partial
correlation
coefﬁcient
(n  278)*
rP
BMI 
0.074 0.222
Waist-to-hip ratio 
0.131 0.031
OGTT glucose (mmol/l)
Fasting glucose 
0.195 0.001
2-h glucose 
0.157 0.009
OGTT insulin (pmol/l)
Fasting insulin† 
0.031 0.612
2-h insulin† 0.002 0.975
HOMA-IR† 
0.107 0.076
A1C (%) 
0.152 0.027
TNF- (ng/ml)† 
0.221 <0.001
IL-6 (pg/ml)† 
0.230 <0.001
hsCRP (mg/l)† 
0.071 0.242
E-selectin (ng/ml) 
0.157 0.009
VCAM-1 (ng/ml) 
0.269 <0.001
ICAM-1 (ng/ml) 
0.026 0.675
*Corrected for age. †The logarithms of these vari-
ables were used for the analysis. Boldface indicates
statistical signiﬁcance.
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lower among patients with new onset of
type 2 diabetes and were associated
with glucose levels, inﬂammation, and
endothelial dysfunction markers. These
ﬁndings demonstrate that Gas6/TAM sig-
naling is associated with type 2 diabetes,
inﬂammation, and endothelial dysfunc-
tion, thereby implicating that Gas6/TAM
signaling may play a potential role in the
pathogenesis of type 2 diabetes, inﬂam-
mation, and endothelial dysfunction.
Increasing evidence indicates that
chronic low-grade inﬂammation and ac-
tivation of the innate immune system are
closely involved in the pathogenesis of
type 2 diabetes (15). Recently, several re-
ports have shown that Gas6/TAM signal-
ing resulted in intrinsic inhibition of the
inﬂammatory response in dendritic cells
and macrophages, which indicated a pos-
sible role of the Gas6 protein in control-
ling innate immunity and inﬂammation
processes (16). For example, TAM triple-
knockout mice with low Gas6 levels
showed hyperactivation of monocytes/
macrophages, and their monocytes re-
acted with an excessive secretion of
TNF-andIL-6afterlipopolysaccharides
challenge (17). Our results revealed that
plasma Gas6 values were lower in type 2
diabetes and also negatively correlated
with inﬂammation markers including
TNF- and IL-6. Therefore, we hypothe-
sized that inﬂammatory effects of high
glucose may be, at least in part, mediated
through low Gas6 levels as well as re-
duced TAM signaling and, consequently,
activated innate immunity.
Several studies have suggested that
the Gas6/TAM system may play a role in
vascular diseases, such as atherosclerosis,
which are characterized by accumulation
of VSMCs. Cavet et al. (11) investigated
the effects of varying glucose concentra-
tion on Axl signaling in VSMCs and dem-
onstrated a role for glucose in altering Axl
signaling through coupling to binding
partners. Recently, Jiang et al. (18) dem-
onstrated that the Gas6 plasma concen-
trations correlated with cardiovascular
disease, especially in patients with acute
coronary syndrome. In addition, Gas6
c.834 	 7GA polymorphism was asso-
ciatedwithalowerriskforcardiovascular
disease. With the exception of VSMCs,
prospective evidence linked endothelial
dysfunction with atherosclerosis, demon-
strating that endothelial dysfunction was
the ﬁrst step in atherosclerosis (19). En-
dothelial dysfunction contributes to
cardiovascular diseases, including hyper-
tension, atherosclerosis, and coronary
heart disease, which are also character-
ized by insulin resistance (20). Two re-
cent studies (21,22) in humans provide
evidence that plasma Gas6 originates
from endothelial cells and leukocytes.
Our results demonstrated that plasma
Gas6 values are signiﬁcantly, but nega-
tively, correlated with the endothelial
dysfunction marker VCAM-1. Mean-
while, using in vitro studies (Y.J. Hung,
C.H. Lee, Y.S. Shieh, unpublished data),
weprovidedevidencethathyperglycemia
can cause endothelial dysfunction with
downregulation of Gas6/TAM signaling.
Hence, we hypothesize that hyperglyce-
miawillleadtodiminishedGas6/TAMre-
ceptor signaling, which may result in
cross-talk between Gas6/TAM signaling
and insulin signaling, thereby inducing
an imbalance in the production of nitric
oxide and endothelin-1 in endothelial
cells.
It can be concluded from this study
that plasma Gas6 levels are associated
with altered glucose tolerance, inﬂamma-
tion,andendothelialdysfunction.Plasma
Gas6 concentration may represent an in-
dependent risk factor of type 2 diabetes
and a potential surrogate marker of in-
ﬂammation and endothelial dysfunction.
These results support the hypothesis that
modulation of Gas6 activity may provide
an important point for intervention.
Gas6/TAM signaling represents a new
class of therapeutic targets. Understand-
ing the nature of the Gas6/TAM interac-
tion would ultimately help in the
development of novel small molecules or
neutralizing monoclonal antibodies for
therapeutic applications for diseases in
which the interaction between Gas6 and
TAM receptors contributes to their pro-
gression or pathology (23).
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